Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018


Here are the related meetings in 2019:
Molecular Approaches to Vaccines and Immune Monitoring (J5)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Emerging Technologies in Vaccine Discovery and Development (J5)


Organizer(s) David Kaslow, Nicholas Jackson and Ann L. Lee
January 28—February 1, 2018
Fairmont Banff Springs • Banff, Alberta Canada
Discounted Abstract Deadline: Oct 4, 2017
Abstract Deadline: Nov 2, 2017
Scholarship Deadline: Oct 4, 2017
Discounted Registration Deadline: Dec 6, 2017

Sponsored by Astellas Pharma Inc., Moderna Therapeutics and Pfizer Inc.
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation


Summary of Meeting:
Immunization remains one of the most effective preventive public health measures, the indirect effects of which are considered a global public good with an impressive net return over costs. Vaccines have contributed to “final public good”: eradication of two viruses and regional elimination of a half dozen or more other pathogens. The development of new vaccines, therefore, would seem an obvious priority area for use-inspired and applied biomedical research, yet the endeavor has become increasingly more challenging. The “easy vaccines have been made” belief, crowded vaccine schedules, escalating costs of full vaccination programs (particularly in cost-sensitive Gavi-eligible countries), and platforms for maternal immunization and Public Health Emergencies of International Concern have all contributed to an urgent need for new or improved approaches to the discovery, development and delivery of vaccines, particularly those that are cheaper, simpler to manufacture, and more convenient to use. The aim of this symposium is to provide a comprehensive survey of emerging tools from the most upstream antigen/vaccine discovery, to active and passive immunization platforms, clinical trials, and manufacturing, formulation and delivery, the desired outcome of which is to provide a forum for an integrated discussion on how best to meet the increasing challenges faced by the scientific community’s efforts in new vaccine development. The Keystone Symposia conference on “Emerging Technologies in Vaccine Discovery and Development” has been specifically paired with the conference on “HIV Vaccines” since discovering, developing and delivering an effective HIV vaccine may be one that benefits most from novel technologies, including new tools in structural immunology and interrogating human immune responses.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, January 28 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 2 in order to fully experience the meeting.

SUNDAY, JANUARY 28

4:00—8:00 PM
Arrival and Registration

Van Horne Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Van Horne Foyer

MONDAY, JANUARY 29

7:00—8:00 AM
Breakfast

Mezzanine 2
8:00—9:00 AM
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Van Horne C
* David C. Kaslow, PATH, USA

Penny M. Heaton, Bill & Melinda Gates Medical Research Institute, USA
Introducing the Gates Medical Research Institute: A Vision for Accelerating Translational Development

8:00—9:00 AM
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
* M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA

Michel C. Nussenzweig, HHMI/Rockefeller University, USA
The HIV Vaccine Problem

9:00—11:30 AM
New Tools in Antigen/Vaccine Discovery
Meeting has ended...abstracts no longer viewable online.

Van Horne C
* Pamela J. Bjorkman, California Institute of Technology, USA

Tobias R. Kollmann, University of British Columbia, Canada
Decoding the Human Immune System to Accelerate Vaccine Development

Coffee Break

Simon Delagrave, Sanofi Pasteur, USA
Novel Antigen Design and Functional Immune Assessments

Rafick-Pierre Sekaly, Case Western Reserve University, USA
Systems Biology and Vaccine Discovery

Sarah F. Andrews, National Institutes of Health, USA
Short Talk: Single-Cell Characterization of the Recall and de novo Responses in Humans to Influenza Hemagglutinin

Hana Golding, US Food and Drug Administration, USA
Short Talk: Impact of AS03 Adjuvant on Antibody Repertoires and Affinity Maturation Against H5N1 Pandemic Influenza Vaccines and Heterologous Neutralization

9:00—11:30 AM
Laying the Foundation for an HIV Vaccine
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
Dennis R. Burton, The Scripps Research Institute, USA
Neutralizing HIV Antibodies and Protection

Coffee Break

Barton F. Haynes, Duke University Medical Center, USA
Host Controls of Broadly Neutralizing Antibodies

* M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Early Clinical Concepts to Advanced Stage HIV Vaccine Studies

Daniel Stieh, Johnson & Johnson, Netherlands
Short Talk: Interim Immunogenicity Analysis of TRAVERSE: A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind phase 1/2a Study in HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of Two Different Prime/Boost Regimens

Tomas Hanke, University of Oxford, UK
Short Talk: Clinical Development of the First -Generation Conserved Region T Cell Vaccines

11:30 AM—5:00 PM
On Own for Lunch

11:30 AM—1:00 PM
Poster Setup

Mezzanine 2
1:00—10:00 PM
Poster Viewing

Mezzanine 2
2:30—4:30 PM
Workshop 1: Assessing Immunogenicity in Animals to Predict Outcomes in Humans

Van Horne C
* Richard Malley, Boston Children's Hospital, USA

Lenny Moise, EpiVax, USA
Immune Engineered H7N9 Influenza Hemagglutinin Overcomes Poor Vaccine Immunogenicity

Clare N. Burn, Albert Einstein College of Medicine, USA
An HSV Vaccine Candidate Deleted in Glycoprotein D Elicits High Titer FcγRIV-Activating Antibodies that Protect against HSV Challenge: A Role for HVEM in Functional Immune Responses

Ian Francis, Boston University, USA
Neisseria Gonorrhoeae Outer Membrane Vesicles Lacking RMP Show Promise as a Vaccine Antigen

Raphael Simon, University of Maryland School of Medicine, USA
Preclinical Development of a Glycoconjugate Vaccine for Sub-Saharan Africa to Prevent Typhoid and Invasive Nontyphoidal Salmonella Disease

Emmanuel Amlabu, University of Ghana, Ghana
Functional Characterization of Plasmodium Falciparum Surface Related Protein (PfSRP) as a Potential Blood-Stage Vaccine Target

Mariette Barbier, West Virginia University, USA
Development of Vaccines against P. Aeruginosa based on Iron Acquisition

Jian-Dong Huang, University of Hong Kong, China
Combination of Multiple Antigens are Essential for the Development of a Novel Vaccine Against Staphylococcus aureus Infection

4:30—5:00 PM
Coffee Available

Van Horne Foyer
5:00—7:00 PM
Structural Immunology Guiding Vaccine Development (Joint)
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
* Pamela J. Bjorkman, California Institute of Technology, USA
Structural Studies of Antibody and Receptor Binding to HIV-1 Env

Jason S. McLellan, University of Texas at Austin, USA
Structure-Based Vaccine Design for Class I Viral Fusion Glycoproteins

Andrew B. Ward, The Scripps Research Institute, USA
Using Structures to Guide Env Immunogen Design and Redesign

Walther Mothes, Yale University School of Medicine, USA
Short Talk: Associating HIV-1 Env Trimer Structures with Functional Env Conformational States by smFRET Analysis

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
7:30—10:00 PM
Poster Session 1

Mezzanine 2

TUESDAY, JANUARY 30

7:00—8:00 AM
Breakfast

Mezzanine 2
8:00—11:30 AM
New Platforms for Active Immunization
Meeting has ended...abstracts no longer viewable online.

Van Horne C
* Louis J. Picker, Oregon Health & Science University, USA

Klaus Früh, Oregon Health & Science University, USA
CMV-Vectored Vaccines for Eliciting Cellular Immunity

Justin Moran, Pfizer Inc., USA
Multi-Component Vaccines Are the Future but Pose Development Challenges

Coffee Break

Richard Malley, Boston Children's Hospital, USA
Generating Broad B- and T-Cell Immunity via the Multiple Antigen-Presenting System (MAPS)

Christine Shaw, Moderna Therapeutics, USA
Targeting Viral Pathogens with mRNA-Based Vaccines

Tong-Ming Fu, Merck Research Laboratories, USA
Short Talk: A Replication-Defective Human Cytomegalovirus Vaccine for Prevention of Congenital Infection

Nadia Oreshkova, Leiden University Medical Center, Netherlands
Short Talk: Engineering Yellow Fever Virus 17D-based RNA Replicons into an Innovative DNA-Launched Vaccine Vector Platform

Jean-Philippe Julien, Hospital for Sick Children Research Institute, Canada
Short Talk: Structural Studies of Human Antibody Responses to Malaria Vaccine Antigen PfCSP

8:00—11:00 AM
Germinal Centers, B/T Cell Interactions
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
* Shane Crotty, La Jolla Institute for Allergy and Immunology, USA
Assessing the Engines of Affinity Maturation: Germinal Centers and Tfh Cells

Gabriel D. Victora, Rockefeller University, USA
Antibody Affinity Maturation in Germinal Centers

Coffee Break

Facundo D. Batista, Ragon Institute of MGH, MIT and Harvard, USA
B Cell Activation Induces a Switch from Canonical to Non-Canonical Autophagy that Shapes B Cell Fate

Kimberly M. Cirelli, La Jolla Institute for Allergy and Immunology, USA
Short Talk: Sustained Delivery Immunization Enhances Germinal Center and Antibody Responses to Env in rhesus macaques

Omolara Olujimi Baiyegunhi, University of KwaZulu-Natal, South Africa
Short Talk: Early Initiation of Antiretroviral Therapy during Hyperacute HIV-1 Infection Preserves T Follicular Helper Cell Function

Ben Read, Massachusetts Institute of Technology, USA
Short Talk: Nanoparticle Delivery, Glycosylation and Host Complement Target Env Immunogens to the Germinal Center

11:30 AM—5:00 PM
On Own for Lunch

11:30 AM—1:00 PM
Poster Setup

Mezzanine 2
11:15 AM—1:00 PM
Hands-On Computer Session on Los Alamos Sequence Database
HIV Database Workshop presented by Los Alamos National Laboratory staff. Topics include: • HIV Sequence Database • Bioinformatics tools that have general application Users can register for either or both workshops. Bring your own laptop.

Baron Shaughnessy
1:00—10:00 PM
Poster Viewing

Mezzanine 2
2:30—4:30 PM
Workshop 2: Epidemic Preparedness Innovation

Van Horne C
* David C. Kaslow, PATH, USA
Just-in-Time and Just-in-Case Vaccines Approaches to Epidemic Preparedness

Christine Dahlke, University Medical Center Hamburg-Eppendorf, Germany
Human miRNome Profiling Identifies a MicroRNA Signature Induced by the Ebola Vaccine rVSV-EBOV

Tulika Singh, Duke University, USA
Transplacental Transfer of IgG in the Setting of Zika Virus Infection during Pregnancy

Neal Scott Van Hoeven, Infectious Disease Research Institute, USA
Development of a Flexible Replicating Viral RNA Vaccine Platform and Generation of a Candidate Vaccine for Zika Virus

Emma M. Kennedy, Public Health England, UK
Development of a Vaccine for Lassa Fever using Modified Vaccinia Ankara Virus as a Vector

Nianshuang Wang, University of Texas at Austin, USA
Structure-Based Design of Prefusion Coronavirus Spikes with Enhanced Expression, Stability and Immunogenicity

Jingjing Jiang, Inovio Pharmaceuticals, USA
Immunogenicity of a Multivalent Mosquito-Borne Virus DNA Vaccine in Non-Human Primates

2:30—4:30 PM
Workshop 1: Laying the Groundwork for Vaccine Design

Van Horne A/B
* Marie Pancera, Fred Hutchinson Cancer Research Center, USA

* Michael Farzan, The Scripps Research Institute, USA

Christopher Andrew Cottrell, The Scripps Research Institute, USA
Using High-Resolution Cryo-Electron Microscopy to Guide Iterative Structure-Based HIV Vaccine Design

Christopher O. Barnes, California Institute of Technology, USA
Structural Characterization of a Highly Potent V3-Targeting Broadly Neutralizing Antibody Bound to Natively-Glycosylated HIV-1 Envelope

Jose Maximiliano Medina-Ramírez, University of Amsterdam, Netherlands
Sequential Vaccination Regimens Based on Multiclade Germline-Targeting Trimers and Affinity Intermediates to Guide bNAb Development

Jason J. Gorman, NIAID, National Institutes of Health, USA
Stabilization of Soluble SIV Envelope Trimers

Wilton Bryan Williams, Duke University, USA
SHIV-CH848 Infection of Rhesus Macaques Recapitulates HIV-1 Env-Antibody Co-Evolution of Humans

Tara A. Bancroft, Fred Hutchinson Cancer Research Center, USA
Detection and in vivo Activation of Naive B Cells Expressing Putative Germline Precursors of a Neutralizing Antibody using Anti-Idiotypes

Devin Sok, International AIDS Vaccine Initiative, USA
Non-human Primate Pharmacokinetics Evaluation of Broadly Neutralizing Antibodies Isolated from Cow Immunizations

Claudia Cicala, NIAID, National Institutes of Health, USA
Select gp120 V2 Domain Specific Antibodies Derived from HIV and SIV Infection and Vaccination Inhibit gp120 Binding to Integrin α4β7

4:30—5:00 PM
Coffee Available

Van Horne Foyer
5:00—7:00 PM
New Platforms for Passive Immunization
Meeting has ended...abstracts no longer viewable online.

Van Horne C
* Charles Richter King, PATH, Malaria Vaccine Initiative, USA

JoAnn A. Suzich, MedImmune, USA
Multi-Mechanistic Monoclonal Antibody-Based Approaches for Passive Immunoprophylaxis

Alejandro Balazs, Massachusetts General Hospital, USA
Development of Vectored Immunotherapy Reveals Escapability as a Key Feature of Broadly Neutralizing Antibodies

Amar Kumar Garg, Indian Institute of Science, India
Short Talk: Stochastic Simulation of Affinity Maturation in Germinal Centers Suggest Optimal Passive Immunization Protocols

Steven E. Bosinger, Emory University, USA
Short Talk: BALDR - A Computational Pipeline for Linking Paired Immunoglobulin Heavy and Light Chain to Gene Expression for Single-Cells in Vaccine Studies

Cody S. Nelson, Duke University, USA
Short Talk: HCMV Glycoprotein B Vaccine Efficacy Likely Mediated by Non-Neutralizing Antibody Effector Functions

5:00—7:00 PM
Model Systems for HIV Vaccine Development
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
* George M. Shaw, University of Pennsylvania, USA
Recapitulation of HIV-1 Envelope-Antibody Coevolution in Rhesus Macaques Leading to Strain-Specific and Broadly Neutralizing Antibodies

Pia Dosenovic, Rockefeller University, USA
Activation of HIV-1-Specific B Cell Precursors in the Presence of a Polyclonal Immune System

Andres Finzi, CRCHUM, Université de Montréal, Canada
Impact of Env Conformation on ADCC Responses

Ann J. Hessell, Oregon Health & Science University, USA
Short Talk: Targeting V1V2 Epitopes for the Development of an Effective HIV Vaccine

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
7:30—10:00 PM
Poster Session 2

Mezzanine 2

WEDNESDAY, JANUARY 31

7:00—8:00 AM
Breakfast

Mezzanine 2
8:00—11:00 AM
New Tools in Interrogating Human Immune Responses (Joint)
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
* Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Computational Tools for Antigen Design

Mohammad M. Sajadi, University of Maryland School of Medicine, USA
The Circulating Antibody Repertoire: Tools of the Trade

Coffee Break

Louis J. Picker, Oregon Health & Science University, USA
Immune Programming with CMV Vectors

Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
Characterizing the Cellular and Humoral Response of Human Volunteers following Dengue Vaccination and Challenge in a Dengue Controlled Human Infection Model

Ian Setliff, Vanderbilt Vaccine Center, USA
Short Talk: Identification of Public Antibody Clonotypes in HIV-1 Infection

11:00 AM—5:00 PM
On Own for Lunch

11:00 AM—1:00 PM
Poster Setup

Mezzanine 2
11:30 AM—1:00 PM
Hands-On Computer Session on Los Alamos Immunology Database
HIV Database Workshop presented by Los Alamos National Laboratory staff Topics include: • HIV Immunology Database • Immunology and vaccine design tools that have general application Users can register for either or both workshops. Bring your own laptop.

Baron Shaughnessy
1:00—10:00 PM
Poster Viewing

Mezzanine 2
2:30—4:30 PM
Workshop 2: Clinical and Preclinical Vaccine Studies

Van Horne A/B
* Nancy L. Haigwood, Oregon Health & Science University, USA

* Alejandro Balazs, Massachusetts General Hospital, USA

Andrew Jones, Emory University, USA
Sublingual and Buccal Delivery of MVA/Protein HIV Vaccination with a Needle-Free Injector Induces Robust Systemic and Mucosal Antibody Responses in Rhesus Macaques

Barbara K. Felber, NCI, National Institutes of Health, USA
DNA+Protein HIV Vaccine Protection against SHIV Challenge upon Same-Site Administration in Macaques

Matthias Georg Pauthner, The Scripps Research Institute, USA
Vaccine-Induced Protection from Autologous Tier 2 SHIV-BG505 Challenge

Keyun Wang, NIAID, National Institutes of Health, USA
Trispecific Broadly Neutralizing HIV Antibodies Mediate Potent SHIV Protection in Macaques

Kristen W. Cohen, Fred Hutchinson Cancer Research Center, USA
Expansion of VH1-2*02 Env-Specific B Cells by Vaccination

Tongqing Zhou, NIAID, National Institutes of Health, USA
Priming with Glycan-deleted HIV-1 Env Trimers and Sequential Boosting with Glycan-Restored Immunogens Induces Immune Responses that Neutralize Diverse Tier-2 Viruses

Daniel P. Leaman, The Scripps Research Institute, USA
Membrane Env Liposomes as a Platform for Immunization with Membrane-Incorporated HIV Env Spikes

Jon Steichen, The Scripps Research Institute, USA
Germline-Targeting for HCDR3-Dependent Broadly Neutralizing Antibodies

4:30—5:00 PM
Coffee Available

Van Horne Foyer
5:00—7:00 PM
New Approaches in Vaccine Clinical Trial Design
Meeting has ended...abstracts no longer viewable online.

Van Horne C
* Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA

Thomas Evans, TomegaVax, USA
Mathematical Modeling of Human Immune Responses to Design more Efficient Vaccine Clinical Development

Ashley J. Birkett, PATH, USA
New Approaches in Vaccine Clinical Trial Design: Maximizing Malaria Vaccine Efficacy and Informing Next-Generation Efforts

Chris Gast, PATH, USA
Novel and More Efficient Vaccine Clinical Trials using Adaptive Designs

Maryam Mukhamedova, NIAID, National Institutes of Health, USA
Short Talk: RSV Antibody Repertoire Analysis from Memory B Cells from RSV DS-Cav1-Vaccinated Adult Volunteers

5:00—7:15 PM
New Insights into HIV/SIV Env Biology and the Function of Non-Neutralizing Antibodies
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
Stuart J. Neil, King's College London, UK
Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction

* Beatrice H. Hahn, University of Pennsylvania, USA
SIVcpz and SIVgor Env-Based Immunogens

Michael Farzan, The Scripps Research Institute, USA
eCD4-Ig Unmasks Epitopes of Non-neutralizing Antibodies in Patient Serum to Mediate Potent ADCC

Lars Hangartner, The Scripps Research Institute, USA
Short Talk: Low-Dose PGT121 Sterilely Protects Macaques in an FcγR-independent Manner from Vaginal Challenge with SHIVSF163P3

Susan Zolla-Pazner, Icahn School of Medicine at Mount Sinai, USA
Short Talk: Induction with V1V2-scaffold Protein Immunogens of Cross-Clade Reactive V2-specific Effector Antibodies with Fc-Mediated Antiviral Functions

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
7:30—10:00 PM
Poster Session 3

Mezzanine 2

THURSDAY, FEBRUARY 1

7:00—8:00 AM
Breakfast

Mezzanine 2
8:00—11:30 AM
New Tools in Vaccine Manufacturing and Product Analytics
Meeting has ended...abstracts no longer viewable online.

Van Horne C
Sangeetha L. Sagar, Sanofi Pasteur, USA
Advances and Challenges in Vaccine Development and Manufacture

* Andrew Lees, Fina Biosolutoins, USA
Talk Title to be Announced

Coffee Break

James N. Thomas, Just Biotherapeutics, USA
Low-Cost Manufacturing and more Stable Immunobiologics for Use in Low and Middle Income Countries

Phillip W. Berman, University of California, Santa Cruz, USA
Breaking the Logjam in HIV Envelope Vaccine Production: Robotics and Gene Editing to Improve Upstream and Downstream Manufacturing Processes

Mark S. Fife, Pirbright Institute, UK
Short Talk: Gene Knockout Technology of Chicken Interferon Inducible Transmembrane Proteins (chIFITMs) for Increased Vaccine Production

Gabriel Byrne, University of California, Santa Cruz, USA
Short Talk: Use of Gene Editing for the Development of an Mgat1 Deficient CHO Cell Line Suitable for GMP Manufacturing of HIV Vaccines

Caroline B. Kjaerulff Mathiesen, Metropolitan University College, University of Copenhagen, Denmark
Short Talk: Genetically Engineered Cell Factories Produce Glycoengineered Vaccines that Target Antigen Presenting Cells and Alter Immunity

8:00—11:15 AM
Induction of Broad Neutralizing Antibodies by Vaccination
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
Leonidas Stamatatos, Fred Hutchinson Cancer Research Center, USA
Targeted Expansion and Maturation of bNAb B Cell Precursors

* John R. Mascola, NIAID, National Institutes of Health, USA
Strategies to Elicit HIV-1 Fusion Peptide Directed Neutralizing Antibodies

Coffee Break

William Schief, IAVI and The Scripps Research Institute, USA
Toward Elicitation of Broadly Neutralizing Antibodies by Germline-Targeted Priming and Structure-Guided Boosting

Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands
Native-Like HIV-1 Envelope Trimers as a Platform to Activate Germline Precursors of Broadly Neutralizing Antibodies

Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Short Talk: Development of Three MPER-directed Neutralizing Antibody Lineages in an HIV Infected Individual

Kevin O. Saunders, Duke University, USA
Short Talk: Modification of HIV Env Glycosylation Augments Binding to Unmutated Common Ancestor and Intermediate Antibodies of V3-Glycan Broadly Neutralizing Antibody Lineages

11:30 AM—5:00 PM
On Own for Lunch

1:00—2:30 PM
Meet the Editors Panel (Joint)
Panel for Students, Postdocs, and Young Investigators to Meet with Journal Editors

Van Horne A/B
Sonja Schmid, Nature Publishing Group, USA

Kavitha Scranton, Immunity, USA

Andrew J. Rennekamp, Cell Press, USA

Lindsey Pujanandez, Science Translational Medicine, USA

2:30—4:30 PM
Workshop 3: How Best to Meet the Increasing Challenges Faced in Vaccine Development

Van Horne C
* Tong-Ming Fu, Merck Research Laboratories, USA

Bruno Emanuel Correia, École Polytechnique Fédérale de Lausanne, Switzerland
On the Development of Precision Vaccines through Epitope-Focused Immunogens: A Case Study on RSV

Lan Zhang, Merck, USA
Design and Characterization of an Improved Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

Michael J. Moser, FluGen, Inc., USA
Single-Replication Influenza B Virus Vaccine BM2SR Provides Sterilizing Immunity and Cross-Lineage Protection by Inducing both Cellular and Cytokine Responses in Mice

Masaru Kanekiyo, NIAID, National Institutes of Health, USA
Targeting the Conserved Stem Supersite on Influenza Virus Hemagglutinin by Human Ighd-Encoded Innate-Like Element

Rahul Shukla, International Centre for Genetic Engineering and Biotechnology, India
“Four-in-One” Envelope-based mosaic VLPs Elicit Tetravalent Neutralizing Antibody Response Devoid of Enhancement Potential in Mice

Guangzu Zhao, University of Queensland, Australia
Self-Adjuvanting and Self-Assembling Lipid Core Peptide Vaccines against Human Hookworm Parasite

Wessam Melik, Orebro University, Sweden
Development of an Edible TBEV Vaccine

Rocio Jimenez-Martinez, Griffith University-QIMRB, Australia
Investigating Venom Derived Molecules that Augment Human Immune Function

4:30—5:00 PM
Coffee Available

Van Horne Foyer
5:00—6:45 PM
New Tools in Vaccine Formulation and Delivery
Meeting has ended...abstracts no longer viewable online.

Van Horne C
* David C. Kaslow, PATH, USA

Nathalie Garçon, Bioaster, France
Adjuvants in Vaccines: From Aluminium to AS01: What Path for their Development and Licensure?

Rhea N. Coler, Infectious Disease Research Institute, USA
Enhancing Immunogenicity and Protective Efficacy through Novel Adjuvants and Formulations

Patrick M. Reeves, Massachusetts General Hospital, USA
Accelerated Development of a T Cell-Based Vaccine for Q Fever

5:00—7:00 PM
Antibodies as Immunoprophylaxis and Treatment
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
Marina F. Caskey, Rockefeller University, USA
Effects of Potent Broad Neutralizing Antibody Combinations in Humans

Julie Ledgerwood, NIAID, National Institutes of Health, USA
Passive Immunization of HIV-1 Neutralizing Monoclonal Antibodies in Clinical Trials

* David D. Ho, Aaron Diamond AIDS Research Center, USA
Engineering HIV-Neutralizing Bispecific Antibodies

Peter D. Kwong, NIAID, National Institutes of Health, USA
Short Talk: Recognition by Antibody of All Major Exposed Regions of the Prefusion Closed HIV-1 Env Trimer

6:45—7:00 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Van Horne C
7:00—7:15 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Van Horne A/B
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Alberta/New Brunswick
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Alberta/New Brunswick

FRIDAY, FEBRUARY 2

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Astellas Pharma Inc. Bill & Melinda Gates Foundation
Moderna Therapeutics Pfizer Inc.

We gratefully acknowledge additional support for this conference from:

Avanti Polar Lipids, Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Sanofi Pasteur


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676